NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of V132 in Healthy Older Participants (V132-001)

NCT07712575

RecruitingPhase 1

Sponsor: Merck Sharp & Dohme LLC

Conditions: Healthy

Interventions: V132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™

Countries: United States

The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.

Eligibility overview

Sex: ALL

Age: 50 Years to 75 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

* Is in good health
* Has body mass index (BMI) within 18.0 to 35.0 kg/m\^2 (inclusive)

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

* Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
* Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study

Locations (9)

Anaheim, California, United States
Hallandale, Florida, United States
Hollywood, Florida, United States
South Miami, Florida, United States
Springfield, Missouri, United States
Lincoln, Nebraska, United States
Omaha, Nebraska, United States
Columbus, Ohio, United States
League City, Texas, United States